In contrast to our in vitro results, which showed only tendential improvement in DB-ADCC by the immune checkpoint blockades, in the tumor-bearing mice, we observed a marked enhancement of DB immunotherapy already by either anti-TIGIT or anti-PD-L1 treatments, with superior effects for the anti-PD-L1 treatment. This evidence concerns the gene CD274 and neoplasm.